

# NA-Fluor™ Influenza Neuraminidase Assay Kit

## Protocol

**For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.**

Information in this document is subject to change without notice.

APPLIED BIOSYSTEMS DISCLAIMS ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. TO THE FULLEST EXTENT ALLOWED BY LAW, IN NO EVENT SHALL APPLIED BIOSYSTEMS BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF, WHETHER OR NOT FORESEEABLE AND WHETHER OR NOT APPLIED BIOSYSTEMS IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

**TRADEMARKS**

The trademarks mentioned herein are the property of Life Technologies or their respective owners.

Triton® is a trademark of Dow Chemical Co. Tamiflu® is a trademark of Hoffmann-La Roche Inc. Relenza® is a trademark of Glaxo Group Limited.

© 2010 Life Technologies. All rights reserved.

Part Number 4457371 Rev. A  
08/2010

# Contents

|            |   |           |
|------------|---|-----------|
|            | <b>About This Guide</b> .....   | <b>5</b>  |
|            | Safety information .....  | 5         |
|            | Safety alert words .....  | 5         |
|            | SDSs .....  | 5         |
| PROTOCOL   | <b>NA-Fluor™ Influenza Neuraminidase Assay Kit</b> .....                      | <b>7</b>  |
|            | Product information .....   | 7         |
|            | Purpose of the product .....  | 7         |
|            | About this protocol .....   | 7         |
|            | Kit contents and storage .....  | 8         |
|            | Materials and equipment required .....  | 8         |
|            | Workflow .....  | 9         |
|            | Titer the virus stock by performing a neuraminidase (NA) activity assay ..... | 10        |
|            | Prepare virus stock serial dilutions and reagents .....                       | 10        |
|            | Perform the NA activity assay .....   | 11        |
|            | Quantitate the NA activity .....  | 12        |
|            | Perform a neuraminidase (NA) inhibition assay .....                           | 14        |
|            | Prepare virus samples and reagents .....                                      | 14        |
|            | Plate layout .....  | 15        |
|            | Perform the NA inhibition assay .....   | 16        |
|            | Determine IC <sub>50</sub> values .....                                       | 17        |
|            | Troubleshoot .....  | 19        |
| APPENDIX A | <b>Ordering and Support Information</b> .....                                 | <b>21</b> |
|            | How to order .....  | 21        |
|            | Support .....   | 21        |
| APPENDIX B | <b>Generate a 4-MU(SS) Standard Curve</b> .....                               | <b>23</b> |
| APPENDIX C | <b>Background information</b> .....   | <b>25</b> |
|            | MUNANA-based neuraminidase assays .....                                       | 25        |
|            | Neuraminidase inhibitor (NI) resistance monitoring .....                      | 25        |

|            |                                |           |
|------------|--------------------------------|-----------|
| APPENDIX D | <b>Safety .....</b>            | <b>27</b> |
|            | Chemical safety .....          | 27        |
|            | General chemical safety .....  | 27        |
|            | SDSs .....                     | 28        |
|            | Chemical waste safety .....    | 28        |
|            | Biological hazard safety ..... | 30        |
|            | <b>References .....</b>        | <b>31</b> |
|            | <b>Index .....</b>             | <b>33</b> |

# About This Guide

## Safety information



**Note:** For general safety information, see this section and [Appendix D, “Safety” on page 27](#). When a hazard symbol and hazard type appear by a chemical name or instrument hazard, see the “Safety” Appendix for the complete alert on the chemical or instrument.

## Safety alert words

Four safety alert words appear in Applied Biosystems user documentation at points in the document where you need to be aware of relevant hazards. Each alert word—**IMPORTANT, CAUTION, WARNING, DANGER**—implies a particular level of observation or action, as defined below:



**IMPORTANT!** – Indicates information that is necessary for proper instrument operation, accurate chemistry kit use, or safe use of a chemical.



**CAUTION!** – Indicates a potentially hazardous situation that, if not avoided, may result in minor or moderate injury. It may also be used to alert against unsafe practices.



**WARNING!** – Indicates a potentially hazardous situation that, if not avoided, could result in death or serious injury.



**DANGER!** – Indicates an imminently hazardous situation that, if not avoided, will result in death or serious injury. This signal word is to be limited to the most extreme situations.

## SDSs

The SDSs for any chemicals supplied by Applied Biosystems are available to you free 24 hours a day. For instructions on obtaining SDSs, see [“SDSs” on page 28](#).



**IMPORTANT!** For the SDSs of chemicals not distributed by Applied Biosystems contact the chemical manufacturer.



# NA-Fluor™ Influenza Neuraminidase Assay Kit

## Product information

### Purpose of the product

The NA-Fluor™ Influenza Neuraminidase Assay Kit (PN 4457091) provides the NA-Fluor™ fluorescent substrate, assay reagents, and protocols to measure neuraminidase (NA) activity from influenza virus. The assay is a direct, functional enzyme assay that detects both known and new mutations that affect neuraminidase inhibitor (NI) drug sensitivity. It uses the MUNANA substrate and generates data that can be compared with data generated using standard Neuraminidase Inhibitor Susceptibility Network (NISN) ([www.nisn.org](http://www.nisn.org)) IC<sub>50</sub> determination protocols.

The assay kit has been optimized for monitoring the effect of NIs on neuraminidase enzyme activity, a method widely used by research or public health laboratories for influenza virus NI susceptibility screening. However, the NA-Fluor™ Influenza Neuraminidase Assay Kit can be used for any application that has been demonstrated using traditional MUNANA assays. These applications include high-throughput screening to identify novel NIs during lead discovery, monitoring NA activity from non-viral sources, or monitoring NI sensitivity in cell-based virus growth or inhibition assays. For more information, see “MUNANA-based neuraminidase assays” on [page 25](#).



**Note:** Applied Biosystems also offers a chemiluminescence-based neuraminidase assay kit: NA-XTD™ Influenza Neuraminidase Assay Kit (PN 4457535).

### About this protocol

This protocol provides procedures for:

- Viral titering based on NA activity
- Neuraminidase enzyme inhibition assays

The procedures in this protocol have been developed and optimized based upon various Neuraminidase Inhibitor Susceptibility Network (NISN) published IC<sub>50</sub> protocols.

## Kit contents and storage

Reagents for ten 96-well microplates are supplied.

| Item   | Volume or Quantity | Storage Conditions         |
|--|--------------------|----------------------------|
| NA-Fluor™ Substrate<br>MUNANA [4-(methylumbelliferyl)-N-acetylneuraminic acid]   | 6.1 mg (5 mL)      | -20 °C, protect from light |
| NA-Fluor™ 2X Assay Buffer<br>66.6 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer, 8 mM CaCl <sub>2</sub> , pH 6.5 | 230 mL             | 2 to 8 °C                  |
| NA-Fluor™ Stop Solution, 0.2 M Na <sub>2</sub> CO <sub>3</sub>   | 110 mL             | 2 to 8 °C                  |

## Materials and equipment required

| Item  | Source  |
|---|---|
| Tissue culture supplies and host cell lines for virus culture preparation   | Multiple laboratory suppliers (MLS <sup>†</sup> )   |
| Reference influenza virus strains (NI-resistant and NI-sensitive sub-type matched)  | ATCC, NISN, or similar influenza reference laboratory<br>NISN provides information for obtaining virus strain sets at <a href="http://nisen.org/v_virus_reference_panel.html">http://nisen.org/v_virus_reference_panel.html</a>               |
| Neuraminidase inhibitors (NIs)<br>• Oseltamivir carboxylate<br>• Zanamivir<br>• Other NIs   | See <a href="http://nisen.org/v_neuraminidase_inhibitor_drugs.html">http://nisen.org/v_neuraminidase_inhibitor_drugs.html</a> for contact information on obtaining NIs.<br>• Roche (Oseltamivir carboxylate)<br>• GlaxoSmithKline (Zanamivir) |
| Distilled water   | Life Technologies PN 4387937 or PN 10977015 at <a href="http://www.invitrogen.com">www.invitrogen.com</a> or similar MLS  |
| 4-Methylumbelliferone sodium salt   | Sigma-Aldrich M1508 or similar  |
| Black, 96-well, flat-bottom plates with plastic lids  | ThermoFisher Scientific NUNC (Cat. No. 237105) or similar MLS   |
| Fluorescence plate reader (excitation range 350 to 365 nm and emission range 440 to 460 nm) (slit widths vary between instruments)  | MLS <sup>†</sup>  |
| Lab equipment<br>• Incubator or plate warmer: 37 °C<br>• Freezer: -20 and -80 °C<br>• Pipettors and tips, single-channel<br>• Pipettors and tips, multi-channel<br>• Microcentrifuge tubes<br>• Reagent reservoirs, single- and multi-well (optional) | MLS <sup>†</sup>  |
| Data analysis software – Dose-response analysis software, such as GraphPad Prism  | GraphPad Software or similar supplier   |

<sup>†</sup> For the SDS of any chemical not distributed by Applied Biosystems, contact the chemical manufacturer. Before handling any chemicals, refer to the SDS provided by the manufacturer, and observe all relevant precautions.



## Workflow

### **Titer the virus stock by performing a neuraminidase (NA) activity assay (page 10)**

Prepare virus stock serial dilutions and reagents (page 10)



Perform the NA activity assay (page 11)



Quantitate the NA activity (page 12)

### **Perform a neuraminidase (NA) inhibition assay (page 14)**

Prepare virus samples and reagents (page 14)



Perform the NA inhibition assay (page 16)



Determine IC<sub>50</sub> values (page 17)

## Titer the virus stock by performing a neuraminidase (NA) activity assay

Determine the NA activity of each new virus strain to determine the optimum virus dilution for the neuraminidase inhibition assay.

NA activity, which is the production of product (4-MU) over time (60 min at 37 °C for the standard assay), is determined by comparing relative fluorescence units (RFU) obtained from an NA activity assay to a standard curve of 4-MU concentrations plotted against RFU values (see “Generate a 4-MU(SS) Standard Curve” on page 23).

Before performing an NA activity assay on an instrument for the first time, generate a 4-MU(SS) standard curve to:

- Determine the linear range of fluorescence versus concentration on your instrument.
- Select an RFU range for normalizing viral strains according to NA activity.

### Prepare virus stock serial dilutions and reagents

**Prepare virus stock** Prepare virus culture supernatants or egg allantoic fluid from single-passage flu virus strains using established culture methods. A comprehensive protocol for influenza virus culture and preparation of viral stocks is available at [http://www.nisn.org/documents/NISN\\_reference\\_panel\\_leaflet.pdf](http://www.nisn.org/documents/NISN_reference_panel_leaflet.pdf) or <http://www.atcc.org>.

**Prepare reagents**

1. Reconstitute NA-Fluor™ Substrate to make a 2.5 mM stock solution:
  - a. Reconstitute the NA-Fluor™ Substrate powder by injecting 5 mL of distilled water into the substrate vial (yields 2.5 mM stock solution).
  - b. Aliquot the 2.5 mM stock solution in 500 µL volumes and store at -20 °C in a non-defrosting freezer protected from light.Use stock aliquots upon thaw and discard unused portions.
2. Prepare 20 mL of 1X assay buffer by adding 50:50 (v/v) 2X NA-Fluor™ Assay Buffer and distilled water (volume needed to prepare substrate working solution and making virus stock serial dilutions).
3. Prepare NA-Fluor™ Substrate 200 µM working solution. For one 96-well assay plate, combine 480 µL of 2.5 mM NA-Fluor™ Substrate stock solution and 5.52 mL of 1X assay buffer.



**Note:** A volume of 480 µL of 2.5 mM stock solution is sufficient for one 96-well assay plate.



**Note:** Protect NA-Fluor™ Substrate working solution from light.

### Compatibility with viral inactivation methods

The NA-Fluor™ Assay is compatible with the following viral inactivation methods:


- 0.1% NP-40 added to the virus sample or viral dilution buffer
- 0.2-1% Triton X-100 added to the virus sample (Jonges et al., 2010) or viral dilution buffer
- 40% ethanol in Stop Solution added during the neuraminidase inhibition assay. For volume sufficient for one 96-well assay microtiter plate, combine 4.8 mL 100% ethanol and 7.2 mL NA-Fluor™ Stop Solution.

### Prepare serial dilutions

Prepare virus stock serial dilutions in a black, 96-well, flat bottom plate. Mix and change tips between dilutions.

1. Add 50 µL of 1X assay buffer to columns 1 to 12 (see Figure 1).
2. Add 50 µL of undiluted virus stock to column 1.
3. Make 2-fold dilutions by transferring 50 µL of undiluted virus stock from column 1 to column 2 and so on, stopping at column 11.
4. Discard 50 µL of volume from column 11.  
Do not add virus to wells in column 12. No Virus Control wells are required on every plate.

Figure 1 Virus stock serial dilutions



### Perform the NA activity assay

1. Add 50 µL of 200 µM NA-Fluor™ Substrate working solution to all wells of the plate.
2. Place the lid on the plate, then incubate at 37 °C for 60 minutes, protected from light. Shaking the plate during incubation recommended.



**Note:** Because the NA-Fluor™ Substrate turnover is linear for up to 4 hours, this enzyme incubation step can be shortened to as low as 30 minutes or extended for up to 2 hours or more. Compare NA activity only between samples assayed for the same incubation periods. Use the same incubation period for the neuraminidase inhibition assay (described on page 14).

3. Terminate the reaction by adding 100 µL of NA-Fluor™ Stop Solution to each well.

- Read the plate using an excitation wavelength range of 350 nm to 365 nm and an emission wavelength range of 440 nm to 460 nm.



**Note:** The plate can be read immediately, up to 4 hours when stored at room temperature, or up to 3 days when stored at 4 °C and protected from light.




**Note:** The NA-Fluor™ assay has been shown to have no phenol red interference.

## Quantitate the NA activity

- Average the relative fluorescence unit (RFU) values of the No Virus Control wells (column 12 in Figure 1 on page 11).
- Subtract the averaged RFU value from the RFU value for each virus dilution to obtain RFU-minus-background values for wells in column 1 to 11.
- Plot the virus dilutions versus RFU-minus-background values.
- For each virus strain, select the dilution factor that yields the RFU value you have identified in your 4-MU(SS) standard curve to use for NA activity normalization.

Figure 2 shows an example plot in which the NA activity for three viruses is plotted against the fluorescence signal. For this example, a fluorescence signal of 28000 RFU corresponding to 10 µM of 4-MU(SS) from a standard curve has been chosen to normalize NA activity. Virus dilutions of ~1:1 for X virus, <1:4 for Y virus, and >1:4 for Z virus correspond to the 28000 RFU range.

Figure 2 Example NA activity plot



Note the following:

- Samples with signal below the linear range of the 4-MU(SS) standard curve may not have sufficient NA activity for inhibition testing and may give inaccurate IC<sub>50</sub> values. For best results, use samples with hemagglutinin (HA) titers ≥20 and/or NA activity within the linear range of the 4-MU(SS) standard curve.
- If it is not possible to obtain samples with ideal viral titer or NA activity, you can use low-titer viral samples for IC<sub>50</sub> determination. To do so, use a viral dilution of the NI-sensitive reference virus or other reference virus strains in which the NA activity is similar to the activity of your low-titer viral sample so that the IC<sub>50</sub> values can be compared under limited NA activity conditions.
- If you are not able to generate a 4-MU(SS) standard curve, use an RFU value that falls within the linear range of your virus dilution versus RFU-background value curve. Use a viral dilution of each viral strain that corresponds to this RFU value for an NA inhibition assay for best comparison between viral strains within the assay.

## Perform a neuraminidase (NA) inhibition assay

Before performing the NA inhibition assay on a new virus strain, titer the virus sample by performing an NA activity assay to determine the optimum dilution of the virus strain (see [page 10](#)).

### Prepare virus samples and reagents

**Reference viruses** The following subtype-matched reference viruses are recommended in each assay run (use reference strains appropriate for virus isolates and NIs you are screening):

- An NI-sensitive strain
- Corresponding strains resistant to zanamivir, oseltamivir carboxylate, or other NI you are using.



**Note:** If you run multiple plates, reference viruses are not required on all plates.

**Prepare samples and reagents**

1. Prepare 20 mL of 1X assay buffer by adding 50:50 (v/v) 2X NA-Fluor™ Assay Buffer and distilled water (volume needed to prepare substrate working solution, prepare the optimum dilution of the virus strain determined [on page 10](#), and make NI serial dilutions).
2. Dilute each virus in 1X assay buffer according to the dilution factor determined in the NA activity assay [on page 10](#).
3. Prepare NA-Fluor™ Substrate 200 µM working solution. For one 96-well assay plate, combine 480 µL of 2.5 mM NA-Fluor™ Substrate stock solution and 5.52 mL of 1X assay buffer.



**Note:** Protect NA-Fluor™ Substrate working solution from light.

**Prepare neuraminidase inhibitors (NIs)**

Bring NIs to ambient temperature before preparing.

Prepare master stock

Prepare a 25 mM master stock of each neuraminidase inhibitor (NI):

- Oseltamivir carboxylate (D-tartrate salt, MW = 386.4) is soluble in water. Dissolve 19.3 mg in 2 mL distilled water.
- Zanamivir (MW = 332.3) is soluble in water up to 18 mg/mL. Dissolve 17.5 mg in 2 mL distilled water.
- Other NIs: Prepare and dissolve according to manufacturer recommendations.

Aliquot and store according to manufacturer recommendations. Avoid freezing-thawing.

Prepare working stock

1. Dilute the 25 mM master stock 1:250 (40 µL 25 mM master stock + 10 mL distilled water) to make a 100 µM working stock. Aliquot in 500 µL volumes and store the working stock according to manufacturer recommendations; use working stock aliquots upon thaw and discard unused portions.

2. Prepare NI serial dilutions at 4X final assay concentration in 1X assay buffer.

| Dilution  | Combine  | NI concentration before assay (4X) | NI concentration in final assay |
|-----------|--|------------------------------------|---------------------------------|
| 1 (1:2.5) | 400 µL WS <sup>†</sup> NI + 600 µL AB <sup>‡</sup> | 40,000 nM                          | 10,000 nM                       |
| 2 (1:10)  | 100 µL Dil 1 + 900 µL AB                           | 4000 nM                            | 1000 nM                         |
| 3 (1:10)  | 100 µL Dil 2 + 900 µL AB                           | 400 nM                             | 100 nM                          |
| 4 (1:10)  | 100 µL Dil 3 + 900 µL AB                           | 40 nM                              | 10 nM                           |
| 5 (1:10)  | 100 µL Dil 4 + 900 µL AB                           | 4 nM                               | 1 nM                            |
| 6 (1:10)  | 100 µL Dil 5 + 900 µL AB                           | 0.4 nM                             | 0.1 nM                          |
| 7 (1:10)  | 100 µL Dil 6 + 900 µL AB                           | 0.04 nM                            | 0.01 nM                         |
| 8 (1:10)  | 900 µL AB  | 0 nM                               | 0 nM                            |

<sup>†</sup> Working Stock = 100 µM NI

<sup>‡</sup> 1X Assay Buffer



**Note:** For compound screening for neuraminidase inhibition, prepare compounds at 4X the desired concentration in 1X assay buffer. A final concentration of 5% DMSO can be tolerated in the assay, although all wells should contain the same concentration of DMSO, including No Virus Control wells.

## Plate layout

Table 1 Plate layout

|                    |   | 1                    | 2 | 3                    | 4 | 5                    | 6 | 7       | 8 | 9       | 10 | 11                            | 12 |
|--------------------|---|----------------------|---|----------------------|---|----------------------|---|---------|---|---------|----|-------------------------------|----|
| Final NI conc (nM) |   |                      |   |                      |   |                      |   |         |   |         |    |                               |    |
| No NI control      | A | Virus 1 <sup>†</sup> |   | Virus 2 <sup>†</sup> |   | Virus 3 <sup>†</sup> |   | Virus 4 |   | Virus 5 |    | No Virus Control <sup>‡</sup> |    |
| 0.01               | B |                      |   |                      |   |                      |   |         |   |         |    |                               |    |
| 0.1                | C |                      |   |                      |   |                      |   |         |   |         |    |                               |    |
| 1                  | D |                      |   |                      |   |                      |   |         |   |         |    |                               |    |
| 10                 | E |                      |   |                      |   |                      |   |         |   |         |    |                               |    |
| 100                | F |                      |   |                      |   |                      |   |         |   |         |    |                               |    |
| 1000               | G |                      |   |                      |   |                      |   |         |   |         |    |                               |    |
| 10000              | H |                      |   |                      |   |                      |   |         |   |         |    |                               |    |

<sup>†</sup> Include reference viruses as appropriate. See ["Reference viruses"](#) on page 14 for recommendations.

<sup>‡</sup> No Virus Control wells are required on every plate.

## Perform the NA inhibition assay

1. Refer to the plate layout in Table 1 on [page 15](#) to prepare the assay plate:



**Note:** This procedure adds NI dilutions to the No Virus Control wells to allow you to determine the effect of NI concentration on assay background RFUs. However, neither oseltamivir nor zanamivir at these concentrations affect NA-Fluor™ assay background. If you choose not to add the NI dilutions to the control, add 25 µL of 1X assay buffer to columns 11 and 12 in step [a](#) instead of 25 µL of the NI dilution series.

- a. Add 25 µL of the 4X NI dilution series to all rows of a 96-well plate: row A (No NI control) through row H (40000 nM NI).
  - b. Add 25 µL of 1X assay buffer to No Virus Control wells in columns 11 and 12.
  - c. Add 25 µL of diluted virus sample to columns 1 to 10 (add virus 1 to column 1 and 2, add virus 2 to column 3 and 4, and so on). Ensure that the virus and NI dilutions are mixed.
2. Place the lid on the plate, then incubate for 20 to 30 minutes at 37 °C. Shaking the plate during incubation is recommended.
  3. Add 50 µL of diluted 200 µM NA-Fluor™ Substrate working solution to each well.
  4. Place the lid on the plate, then incubate for 60 minutes at 37 °C protected from light. Shaking the plate during incubation is recommended.



**Note:** Because NA-Fluor™ Substrate turnover is linear for up to 4 hours, this enzyme incubation step can be shortened to as low as 30 minutes or extended for up to 2 hours or more. Compare only IC<sub>50</sub> values between samples assayed for the same incubation periods. IC<sub>50</sub> values may vary slightly over time due to inhibitor off-rates.

5. Terminate the reaction by adding 100 µL of NA-Fluor™ Stop Solution to all wells. Stop Solution also enhances signal and stabilizes the fluorescent reaction product.



**Note:** The NA-Fluor™ assay can also be performed in real-time without the addition of NA-Fluor™ Stop Solution using the kinetic read option on your fluorescent plate reader. Fluorescent signal is typically 5 to 6 fold lower without the high pH shift provided by the NA-Fluor™ Stop Solution. At 37 °C, the rate of NA-Fluor™ Substrate turnover by viral neuraminidase remains linear for up to 4 hours. The assay can be terminated with NA-Fluor™ Stop Solution and the plate re-read at any time point.

6. Read the plate using an excitation wavelength range of 350 nm to 365 nm and an emission wavelength range of 440 nm to 460 nm.



**Note:** The plate can be read immediately, up to 4 hours when stored at room temperature, or up to 3 days when stored at 4 °C and protected from light.



## Determine IC<sub>50</sub> values

Determine IC<sub>50</sub> values from dose-response data using sigmoidal curve-fitting or point-to-point plotting. You can use any software that can perform sigmoidal curve-fitting or point-to-point plotting.

See the NISN web site (<http://www.nisn.org>) for detailed information on determining, interpreting, and troubleshooting IC<sub>50</sub> results, and for criteria for defining NI-resistant virus strains.

1. Average the RFU (relative fluorescence unit) values of the No Virus Control wells.
2. Subtract the averaged RFU value from the RFU value of all wells to obtain RFU-minus-background values.
3. Plot NI concentration (in nM or M) versus RFU-minus-background values using non-linear curve fitting in GraphPad Prism software or other software.  
This plot should yield a sigmoid dose-response curve.

### Guidelines for GraphPad Prism Software

This section provides some guidelines for analyzing data if you use GraphPad Prism Software for sigmoidal curve-fitting of dose response data (for more information, see the *GraphPad Prism Step-by-Step Examples Guide* or contact the manufacturer).

1. Select the graph type (typically XY, points only graph with Y error bars) and number of replicates.
2. Enter data:
  - a. X Values: enter NI concentrations in molar concentration in exponential notation. Enter a concentration that is 100 to 1000-fold lower than lowest NI dilution to use as the “0” NI value.
  - b. Y Values: enter response data in appropriate sets of Y columns. Raw signal intensity (RFU-minus-background dose response) data is exported into software.
3. Data manipulation/analyze:
  - a. Log Transform X Values: in Analyze:Transforms dialog box, select X=Log(X)
  - b. Normalize Y Values: in the Analyze:Normalize dialog box, define 0% as the smallest values and 100% as the highest values (default), present results as Percentages and Create a new graph.
4. Curve-fitting:
  - a. With the graph generated above displayed, click Analyze:Nonlinear regression, select Sigmoidal dose-response (variable slope), (same as “four-parameter logistic” in other graphing programs).
  - b. (Optional) Constrain curve-fit parameters by clicking the Constraints tab and set BOTTOM parameter to 0.0 and TOP parameter to 100.0.





**Note:** Constraining the parameters may alter the determined IC<sub>50</sub> value.

**5. Graph adjustments:**

- a.** Values/data from the Results page can be copied/pasted onto the Graph page to display curve-fit parameters on graph.
- b.** X-axis and Y-axis adjustments can be made to alter range, to segment the X-axis, change concentration display, etc.

## Troubleshoot

**Table 2** Neuraminidase inhibition assay troubleshooting

| Observation   | Possible cause  | Recommended action   |
|---|---|--|
| Higher than expected background fluorescence signal in No Virus Control wells   | NA-Fluor™ Substrate not stored at -20 °C  | Use properly stored NA-Fluor™ Substrate.   |
|   | Reagent contamination with a neuraminidase source (viral, bacterial, fungal, or other source) | Use fresh reagents.  |
| Low signal  | Instrument incorrectly set up   | Set for an excitation wavelength range of 350 nm to 365 nm and an emission wavelength range of 440 nm to 460 nm.   |
|   | Reagent contamination with a neuraminidase inhibitor (NI).                                    | Use fresh reagents.  |
|   | Low virus concentration and/or low neuraminidase (NA) activity                                | Use a higher virus titer or a higher dilution of the same titer.<br><br> <b>Note:</b> If it is not possible to obtain samples with ideal viral titer or NA activity, you can use low-titer viral samples for IC <sub>50</sub> determination. To do so, use a viral dilution of the NI-sensitive reference virus or other reference virus strains in which the NA activity is similar to the activity of your low-titer viral sample so that the IC <sub>50</sub> values can be compared under limited NA activity conditions. |
|   |   | Extend the 60-minute incubation step up to 2 hours.  |
|   |   | Use the NA-XTD™ Influenza Neuraminidase Assay Kit (PN 4457535) which provides higher detection sensitivity.  |
| The RFU values for the highest NI concentration are not comparable to the RFU values for the No Virus Control (which does not contain virus), and will yield inaccurate IC <sub>50</sub> values | NI dilution series not optimized  | Optimize the NI dilution series using a higher starting concentration of NI.<br><br> <b>Note:</b> Resistant strains may require higher NI concentrations to maximize inhibition.  |
| The RFU values for the lowest NI concentration are not comparable to the RFU values for the No NI Control, and will yield inaccurate IC <sub>50</sub> values                                    | NI dilution series not optimized  | Optimize the NI dilution series so that the lowest NI concentration does not yield inhibition.   |



# Ordering and Support Information

## How to order

To place an order online, go to [www.appliedbiosystems.com](http://www.appliedbiosystems.com).

To place an order from the U.S. or Canada, dial 1-800-345-5224, then follow the voice instructions.

To place an order outside the U.S., go to [www.appliedbiosystems.com](http://www.appliedbiosystems.com) to locate your nearest Applied Biosystems office.

| Description                                 | Quantity   | Part Number |
|---|--|-------------|
| NA-Fluor™ Influenza Neuraminidase Assay Kit | Reagents sufficient for 960 assays (100 µL) or ten 96-well assay microplates | 4457091     |

## Support

For the latest services and support information for all locations, go to:

[www.appliedbiosystems.com](http://www.appliedbiosystems.com)

At the Applied Biosystems web site, you can:


- Access worldwide telephone and fax numbers to contact Applied Biosystems Technical Support and Sales facilities (for Product/Area, select **Chemiluninescence/Tropix**).
- Search through frequently asked questions (FAQs).
- Submit a question directly to Technical Support.
- Order Applied Biosystems user documents, SDSs, certificates of analysis, and other related documents.
- Download PDF documents.
- Obtain information about customer training.
- Download software updates and patches.



# Generate a 4-MU(SS) Standard Curve

4-Methylumbelliferone (4-MU), the end product of MUNANA cleavage by neuraminidase, can be used to determine the linear range of substrate turnover detection on your specific instrument.

Generate a 4-Methylumbelliferone sodium salt (4-MU(SS)) standard curve to identify an RFU value within the linear range of fluorescence detection on your instrument. For each viral strain, use the dilution factor that best corresponds to the chosen RFU value from the 4-MU(SS) standard curve. This method can be applied for each viral strain to normalize the NA activities of each virus strain for use in the NI assay for best intra-assay comparison of data.

 **IMPORTANT!** Fluorescence units are relative (the total number of RFUs is different on different instruments).

1. Prepare 100 mM stock 4-MU(SS) (Sigma M1508) by adding 198.1 mg to 10 mL of distilled water. To make working solution of 100  $\mu$ M, make a 1:1000 dilution in distilled water.



**Note:** Note: Protect 4-MU(SS) solution from light.

2. Serially dilute 4-methylumbelliferone sodium salt (4-MU(SS)) master stock solution (100 mM, Sigma-Aldrich M1508 or similar) in 2-fold dilutions, in NA-Fluor™ Stop Solution.

| Dilution   | Combine  | Concentration |
|------------|--|---------------|
| 1 (1:1000) | 1 $\mu$ L WS <sup>†</sup> + 1000 $\mu$ L SS <sup>‡</sup> | 100 $\mu$ M   |
| 2 (1:2)    | 500 $\mu$ L Dil 1 + 500 $\mu$ L SS                       | 50 $\mu$ M    |
| 3 (1:2)    | 500 $\mu$ L Dil 2 + 500 $\mu$ L SS                       | 25 $\mu$ M    |
| 4 (1:2)    | 500 $\mu$ L Dil 3 + 500 $\mu$ L SS                       | 12.50 $\mu$ M |
| 5 (1:2)    | 500 $\mu$ L Dil 4 + 500 $\mu$ L SS                       | 6.25 $\mu$ M  |
| 6 (1:2)    | 500 $\mu$ L Dil 5 + 500 $\mu$ L SS                       | 3.12 $\mu$ M  |
| 7 (1:2)    | 500 $\mu$ L Dil 6 + 500 $\mu$ L SS                       | 1.56 $\mu$ M  |
| 8 (1:2)    | 500 $\mu$ L Dil 7 + 500 $\mu$ L SS                       | 0.78 $\mu$ M  |
| 9 (1:2)    | 500 $\mu$ L Dil 8 + 500 $\mu$ L SS                       | 0.39 $\mu$ M  |
| 10 (1:2)   | 500 $\mu$ L Dil 9 + 500 $\mu$ L SS                       | 0.20 $\mu$ M  |
| 11 (1:2)   | 500 $\mu$ L Dil 10 + 500 $\mu$ L SS                      | 0.10 $\mu$ M  |
| 12 (1:2)   | 500 $\mu$ L SS   | N/A           |

<sup>†</sup> Working Stock (WS) = 100 mM in 4-MU(SS) in distilled water


<sup>‡</sup> NA-Fluor™ Stop Solution (SS) is used to enhance fluorescence and provides the same conditions as the NA activity assay.

3. Pipette 200  $\mu\text{L}$  of each serial dilution of 4-MU(SS) in duplicate into a black, 96-well, flat bottom plate. (The standard curve 200  $\mu\text{L}$  volume is equal to the 200  $\mu\text{L}$  of the NA activity assay volume.)
4. Read the plate using an excitation wavelength range of 350 nm to 365 nm and an emission wavelength range of 440 nm to 460 nm.
5. Plot RFU versus 4-MU(SS) concentrations. Figure 3 illustrates a 4-MU(SS) standard curve.
6. Determine the NA activity/RFU range you will use for the NA inhibition assay.  
 Example (Figure 4): You decide to perform all NI assays using an NA activity of 10  $\mu\text{M}$  4-MU/60 min at 37  $^{\circ}\text{C}$ . On the fluorescence reader used to generate the standard curve in this example, 10  $\mu\text{M}$  4-MU corresponds to ~28,000 RFU. You would then use viral dilutions corresponding to ~28,000 RFU for each viral sample surveyed in an NI assay.




**Note:** The choice of 10  $\mu\text{M}$  4-MU is arbitrary within the linear range. Lower NA-activity equivalents such as 2  $\mu\text{M}$  4-MU also fall within the linear range of detection in this example. Do not select a concentration that is outside the linear range (for example, 20  $\mu\text{M}$  in the curve below), where instrument signal may be saturated and small changes in fluorescence are not detectable.

**Figure 3** 4-MU(SS) standard curve, linear range shown in box



**Figure 4** Example: Determine the NA activity/RFU range for the NA inhibition assay using the linear range of 4 MU(SS) standard curve shown in box in Figure 3



Example:  
 To normalize at 10  $\mu\text{M}$  4-MU  
 NA activity, use an RFU  
 range ~28,000



# Background information

## MUNANA-based neuraminidase assays

The NA-Fluor™ Influenza Neuraminidase Assay Kit provides a standardized fluorescence-based assay, which quantitates the fluorogenic end product 4-methylumbelliferone released from the non-fluorescent substrate 2'-(4-methylumbelliferyl)- $\alpha$ -D-N-acetylneuraminic acid (MUNANA) by the enzymatic activity of neuraminidase. The amount of fluorescence directly relates to the amount of enzyme activity.

MUNANA-based neuraminidase (NA) assays have been used for NA activity quantitation in detection and monitoring of influenza virus growth or growth inhibition in cell-based assays, as well as NA activity from other viruses and organisms, including bacteria, mammals, parasites. MUNANA-based assays have been widely used in high throughput screening for new neuraminidase inhibitors (NIs) and influenza virus surveillance around the globe. Influenza replication has been measured with MUNANA substrate using AVINA assay (Accelerated Viral Inhibition with NA as read-out assay) for drug toxicity evaluation (Eichelberger et al., 2008). AVINA assays developed using MUNANA substrate measures viral growth inhibition in the presence of inhibitory antibodies or compounds (Hassantoufighi, et al., (2010).

## Neuraminidase inhibitor (NI) resistance monitoring

Viral neuraminidase is the target of key antiviral drugs effective in treating the influenza strains that are currently considered world-health threats. Influenza virus neuraminidase functions by allowing release of newly formed viral particles from a host cell by cleaving terminal N-acetyl neuraminic acid (sialic acid) which serves as the attachment site between the viral hemagglutinin (HA) protein and glycoconjugates on the host cell surface. Neuraminidase inhibitor (NI) drugs, including oseltamivir (Tamiflu®) and zanamivir (Relenza®), as well as drugs awaiting approval, act by binding competitively to the active site of the neuraminidase, thus inhibiting release and spread of the virus. Mutations in viral neuraminidase have been identified which render the virus resistant to NIs, resulting in the need to survey influenza-strain susceptibility to this class of antiviral drugs. Viral susceptibility or resistance can be monitored by measuring the drug inhibitory effect on NA enzyme activity.

NI resistance monitoring is critical to track treatment efficacy and global spread of resistant viral strains for seasonal, avian, animal and pandemic strains. Increasingly, since the introduction of neuraminidase inhibitor therapeutics in 1999, mutations conferring resistance to neuraminidase inhibitors are arising and spreading, with seasonal A/H1N1 isolates predominantly resistant to oseltamivir globally. Functional neuraminidase inhibition assays enable detection of any resistance mutation, and are therefore extremely important in conjunction with sequence-based screening assays for global monitoring of virus isolates for NI resistance mutations, including known and new mutations.



# Safety

This appendix covers:

|                                |    |
|--------------------------------|----|
| ■ Chemical safety .....        | 27 |
| General chemical safety .....  | 27 |
| SDSs .....                     | 28 |
| Chemical waste safety .....    | 28 |
| Biological hazard safety ..... | 30 |

## Chemical safety

### General chemical safety

Chemical hazard  
warning



**WARNING! CHEMICAL HAZARD.** Before handling any chemicals, refer to the Safety Data Sheet (SDS) provided by the manufacturer, and observe all relevant precautions.



**WARNING! CHEMICAL HAZARD.** All chemicals in the instrument, including liquid in the lines, are potentially hazardous. Always determine what chemicals have been used in the instrument before changing reagents or instrument components. Wear appropriate eyewear, protective clothing, and gloves when working on the instrument.



**WARNING! CHEMICAL HAZARD.** Four-liter reagent and waste bottles can crack and leak. Each 4-liter bottle should be secured in a low-density polyethylene safety container with the cover fastened and the handles locked in the upright position. Wear appropriate eyewear, clothing, and gloves when handling reagent and waste bottles.



**WARNING! CHEMICAL STORAGE HAZARD.** Never collect or store waste in a glass container because of the risk of breaking or shattering. Reagent and waste bottles can crack and leak. Each waste bottle should be secured in a low-density polyethylene safety container with the cover fastened and the handles locked in the upright position. Wear appropriate eyewear, clothing, and gloves when handling reagent and waste bottles.



## Chemical safety guidelines

To minimize the hazards of chemicals:

- Read and understand the Safety Data Sheets (SDSs) provided by the chemical manufacturer before you store, handle, or work with any chemicals or hazardous materials. (See “About SDSs” on page 28.)
- Minimize contact with chemicals. Wear appropriate personal protective equipment when handling chemicals (for example, safety glasses, gloves, or protective clothing). For additional safety guidelines, consult the SDS.
- Minimize the inhalation of chemicals. Do not leave chemical containers open. Use only with adequate ventilation (for example, fume hood). For additional safety guidelines, consult the SDS.
- Check regularly for chemical leaks or spills. If a leak or spill occurs, follow the manufacturer’s cleanup procedures as recommended in the SDS.
- Comply with all local, state/provincial, or national laws and regulations related to chemical storage, handling, and disposal.

## SDSs

### About SDSs

Chemical manufacturers supply current Safety Data Sheets (SDSs) with shipments of hazardous chemicals to new customers. They also provide SDSs with the first shipment of a hazardous chemical to a customer after an SDS has been updated. SDSs provide the safety information you need to store, handle, transport, and dispose of the chemicals safely.

Each time you receive a new SDS packaged with a hazardous chemical, be sure to replace the appropriate SDS in your files.

### Obtaining SDSs

The SDS for any chemical supplied by Applied Biosystems is available to you free 24 hours a day. To obtain SDSs:

1. Go to [www.appliedbiosystems.com](http://www.appliedbiosystems.com), click **Support**, then select **SDS**.
2. In the Keyword Search field, enter the chemical name, product name, SDS part number, or other information that appears in the SDS of interest. Select the language of your choice, then click **Search**.
3. Find the document of interest, right-click the document title, then select any of the following:
  - **Open** – To view the document
  - **Print Target** – To print the document
  - **Save Target As** – To download a PDF version of the document to a destination that you choose



**Note:** For the SDSs of chemicals not distributed by Applied Biosystems, contact the chemical manufacturer.

## Chemical waste safety

### Chemical waste hazards



**CAUTION! HAZARDOUS WASTE.** Refer to Safety Data Sheets and local regulations for handling and disposal.



**WARNING! CHEMICAL WASTE HAZARD.** Wastes produced by Applied Biosystems instruments are potentially hazardous and can cause injury, illness, or death.



**WARNING! CHEMICAL STORAGE HAZARD.** Never collect or store waste in a glass container because of the risk of breaking or shattering. Reagent and waste bottles can crack and leak. Each waste bottle should be secured in a low-density polyethylene safety container with the cover fastened and the handles locked in the upright position. Wear appropriate eyewear, clothing, and gloves when handling reagent and waste bottles.

## Chemical waste safety guidelines

To minimize the hazards of chemical waste:

- Read and understand the Safety Data Sheets (SDSs) provided by the manufacturers of the chemicals in the waste container before you store, handle, or dispose of chemical waste.
- Provide primary and secondary waste containers. (A primary waste container holds the immediate waste. A secondary container contains spills or leaks from the primary container. Both containers must be compatible with the waste material and meet federal, state, and local requirements for container storage.)
- Minimize contact with chemicals. Wear appropriate personal protective equipment when handling chemicals (for example, safety glasses, gloves, or protective clothing). For additional safety guidelines, consult the SDS.
- Minimize the inhalation of chemicals. Do not leave chemical containers open. Use only with adequate ventilation (for example, fume hood). For additional safety guidelines, consult the SDS.
- Handle chemical wastes in a fume hood.
- After emptying a waste container, seal it with the cap provided.
- Dispose of the contents of the waste tray and waste bottle in accordance with good laboratory practices and local, state/provincial, or national environmental and health regulations.

## Waste disposal

If potentially hazardous waste is generated when you operate the instrument, you must:

- Characterize (by analysis if necessary) the waste generated by the particular applications, reagents, and substrates used in your laboratory.
- Ensure the health and safety of all personnel in your laboratory.
- Ensure that the instrument waste is stored, transferred, transported, and disposed of according to all local, state/provincial, and/or national regulations.



**IMPORTANT!** Radioactive or biohazardous materials may require special handling, and disposal limitations may apply.



## Biological hazard safety

### General biohazard



**WARNING! BIOHAZARD.** Biological samples such as tissues, body fluids, infectious agents, and blood of humans and other animals have the potential to transmit infectious diseases. Follow all applicable local, state/provincial, and/or national regulations. Wear appropriate protective equipment, which includes but is not limited to: protective eyewear, face shield, clothing/lab coat, and gloves. All work should be conducted in properly equipped facilities using the appropriate safety equipment (for example, physical containment devices). Individuals should be trained according to applicable regulatory and company/institution requirements before working with potentially infectious materials. Read and follow the applicable guidelines and/or regulatory requirements in the following:

- U.S. Department of Health and Human Services guidelines published in *Biosafety in Microbiological and Biomedical Laboratories* (stock no. 017-040-00547-4; [bmbi.od.nih.gov](http://bmbi.od.nih.gov))
- Occupational Safety and Health Standards, Bloodborne Pathogens (29 CFR§1910.1030; [www.access.gpo.gov/nara/cfr/waisidx\\_01/29cfr1910a\\_01.html](http://www.access.gpo.gov/nara/cfr/waisidx_01/29cfr1910a_01.html)).
- Your company's/institution's Biosafety Program protocols for working with/handling potentially infectious materials.

Additional information about biohazard guidelines is available at:

[www.cdc.gov](http://www.cdc.gov)

# References

NISN IC<sub>50</sub> Methodology (<http://www.nisn.org/>):

- Marathe, BM, and Govorkova, EA(2010). Determination of Influenza Virus Susceptibility to Neuraminidase Inhibitors Using a Fluorescent Substrate. St. Jude Children's Research Hospital.
- Hurt, A (2009). Fluorometric Neuraminidase Inhibition Assay. Standard Operating Procedure, WHO – 025. WHO Collaborating Centre for Reference and Research on Influenza, Australia.
- McKimm-Breschkin, J. NA Enzyme Inhibition Assay for Sensitivity to NA Inhibitors. Fluorescence Based Assay (MUNANA).
- Lackenby, A (2008). Determination of Influenza Virus Susceptibility to Neuraminidase Inhibitors Using a Fluorescent Substrate.

Hassantoufighi, et al (2010). A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. *Vaccine* 28:790-797.

Jonges, M, et al (2010). Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. *J Clin Microbiol* 48(3):928-940.

Li, Aifeng, et al (2009). A microplate-based screening assay for neuraminidase inhibitors. *Drug Discov. Ther.*; 3(6):260-265

Eichelberger, MC, et al (2008). Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. *Virology Journal* 5:109.

Ailin, Liu, et al (2005). Drug screening for influenza neuraminidase inhibitors. *Science in China Ser. C Life Sciences* Vol.48 No.115.

Mungall, BA, et al (2003). Assaying susceptibility of avian and other influenza A viruses to Zanamivir: Comparisons of fluorescent and chemiluminescent neuraminidase assays. *Avian Diseases* 47:1141-1144.

Wetherall, NT, et al (2003). Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network. *J Clin Microbiol* 41(2):742-750.





## Numerics

1X assay buffer 10

4-MU(SS) standard curve 23

## B

biohazardous waste, handling 30

## C

CAUTION, description 5

chemical safety 27, 28

chemical waste safety 28, 29

compatibility with viral inactivation methods 11

compound screening 15

## D

DANGER, description 5

## G

GraphPad software 17

guidelines

chemical safety 28

chemical waste disposal 28

chemical waste safety 29

## H

hazards. *See* safety

how to order 21

## I

IC<sub>50</sub>, determine 17

IMPORTANT, description 5

incubation times 16

## K

kit

contents and storage 8

description 7

## M

materials 8

MUNANA-based neuraminidase assays 25

## N

neuraminidase activity

assay 10, 11

normalize 12

quantitate 12

neuraminidase inhibition assay

IC<sub>50</sub> 17

protocol 16

neuraminidase inhibitors

obtain 8

prepare 14

resistance monitoring 25

normalize neuraminidase activity 12

## O

ordering, how to 21

## P

phenol red interference 12

product information 7

product, purpose of 7

## R

radioactive waste, handling 29

reagents, prepare 10, 14

reference viruses 8, 14

## S

safety

biological hazards 30

chemical 27

chemical waste [28](#)  
guidelines [28](#), [29](#)

SDSs

about [5](#)  
description [28](#)  
obtaining [21](#), [28](#)

standard curve, 4-MU(SS) [23](#)

storage conditions [8](#)

substrate, prepare [10](#)

## T

titer virus stock [10](#)

training, information on [21](#)

troubleshoot [19](#)

## V

viral inactivation method compatibility [11](#)

virus stock

dilutions [11](#), [14](#)  
prepare [10](#)  
titer [10](#)

virus, reference [8](#), [14](#)

## W

WARNING, description [5](#)

waste disposal, guidelines [29](#)

waste profiles, description [29](#)

workflow [9](#)

Part Number 4457371 Rev. A 08/2010



**Headquarters**

5791 Van Allen Way | Carlsbad, CA 92008 USA  
Phone 760.603.7200  
[www.lifetechnologies.com](http://www.lifetechnologies.com)

**Technical Resources and Support**

For the latest technical resources and support information  
for all locations, please refer to our Web site at  
[www.appliedbiosystems.com](http://www.appliedbiosystems.com)